MGI Submits Saforis NDA: Pipeline To Propel Sales To $1 Bil. By 2010 – Firm
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.